MDVN (Medivation)
All Pro Portfolios with MDVN
- Total Pro Portfolios with MDVN:
- QVT Financial LP
- show more
- 1
All Do-It-Yourself Portfolios with MDVN
- Total Do-It-Yourself Portfolios with MDVN:
- EW Portfolio 1
- Zenka Stocks
- lostlemming Portfolio 1
- PANTERA.GROUP 85
- Eagle6 Portfolio 1
- treasure_house Portfolio 1
- trialphaman Portfolio 1
- mnuge Portfolio 1
- jtfplasty@comcast.net Portfolio 1
- ljbond Portfolio 1
- sbII
- Barron's 2008 Roundtable Stock Picks
- ASCO is coming...Papers released May 15
- ASCO 2009 Nymph's Watch List.
- Healthcare Short Squeezes for the Week
- show more
- 29
- The Fantastic Voyage
- vip
- theebdk Portfolio 1
- rickyy7 Portfolio 1
- Wolf2fly's BioTech Picks
- ELNINO
- barret Portfolio 1
- cookster Portfolio 1
- chuck93 Portfolio 1
- Sean's Stocks
- EGI Portfolio
- Steamers
- PART 5 JPMorgan 27th Annual Healthcare Conf 1/14/09..3rd Day Reporting Companies..Nymph Take
- Fast Money's Cancer Breakthrough Stocks
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:RhinoStocks |
Date:10 05 09 |
Short Interest Ratio: 26.8 |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:06 03 09 |
Huckman said some of the companies to watch are OSI Pharma(OSIP) which is expected to release test results on a cancer drug this weekend, and Medivation(MDVN), which is due to come out with some prostate cancer drug results. |
|
Not yet rated
Rate now:
|
|
Date:12 30 08 |
|
10 |
|
Not yet rated
Rate now:
|
|
By:Dan Jacobs |
Date:01 14 08 |
Medivation. Oscar Shafer's pick in Barron's roundtable. The drug has a lead compound in trials for Alzheimer's disease. |
|
Not yet rated
Rate now:
|
|
By:Dan Jacobs |
Date:01 14 08 |
Medivation. Oscar Shafer's pick in Barron's roundtable. The drug has a lead compound in trials for Alzheimer's disease. |
|
Not yet rated
Rate now:
|
|
By:barrons2 |
Date:01 12 08 |
Schafer: My second company is Medivation. Its market capitalization is only about $400 million. It is a bio-pharmaceutical company focused on acquiring and developing small-molecule drugs. Its lead compound, Dimebon, is designed to treat Alzheimer's and Huntington's disease. Its other product is a once-daily oral treatment for prostate cancer. |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |
